

Market Analysis

Biomarkers 2020 - Market Analysis

Giulio Tarro


Professor, Foundation T. & L De Beaumont Bonelli for Cancer Research, Napoli, Italy, E-mail: giuliotarro@gmail.com

Overview on Biomarkers Market

The global biomarkers market has increased demand in recent years due to the rapid growth of population, rapid growth in IT industry which leads to increasing efforts towards the drug discovery. The entry of new entrepreneurs is expected to further boost the growth of the market. The advancements and innovations of biomarkers in medical arena such as research and cancer treatment will propel the future growth of the global biomarkers market. Biomarkers are broadly used to detect diseases such as immunological disorders, neurological disorders, cancer, cardiovascular disorders, and others. In the arena of oncology, recently three biological markers have been added to conventional breast cancer risk models to identify women at a higher risk of breast cancer


Global Vocal Biomarkers Market

Sound vibrations are used as part of therapeutic healing for various mental health conditions such as anxiety and depression. Recent research studies, however, have greatly widened its applications into diagnosis of various diseases. On successful completion of clinical trials, HIPAA compliant vocal biomarker system would serve as much more alternative methods to current diagnostic techniques such as MRI, X-Ray, and CT scan. Research is also ongoing for identifying vocal biomarkers in diagnosis of Parkinson's disease, traumatic brain injury, cognitive impairment, and respiratory disorders, which would open up a highly profitable avenue for growth for players in this industry. Since last 22 years companies dealing with vocal biomarkers are on researching by sampling data to provide accurate results and it has collected over 2.5 million voice samples in over 40 different languages.




Global Biomarkers Market is expected to USD 78.9 billion by 2024, from USD 31.4 billion in 2016 growing at a CAGR of 12.2% during the forecast period of 2017 to 2024. The new market report contains data for historic years 2014 & 2015, the

base year of calculation is 2016 and the forecast period is 2017 to 2024.



Regional analysis includes:

- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Western Europe (Germany, Italy, U.K, Spain, France, Rest of Western Europe)
- Eastern Europe (Russia)
- Asia Pacific (China, India, ASEAN, Australia & New Zealand)
- Japan
- Middle East and Africa (GCC, S. Africa)



Summary (Overall Market of Biomarkers & Clinical Research with Statistics)

The global biomarkers market is expected to reach \$45.55 Billion by 2020 from \$24.10 Billion in 2015, at a CAGR of 13.58% between 2015 and 2020. Increasing healthcare expenditure & R&D spending and the increasing utility of biomarkers for diagnostics are expected to drive the market. Market growth will also be aided by the low cost of clinical trials in developing countries and new initiatives undertaken for biomarker research. On the other hand, the need for high capital investment, low benefit-cost ratio, poorly suited regulatory & reimbursement systems, and the high cost of tests and sample collection & storage are the major factors restraining the growth of this market.

The applications included in this report are diagnostics development, drug discovery & development, personalized medicine, disease risk assessment and other applications. The disease indication segments included in this report are cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases. Major players in this market include QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (U.S.), Merck & Co, Inc. (U.S.), Bio-Rad Laboratories (U.S.), Enzo Biochem (U.S.), EKF Diagnostics Holdings plc (U.S.), Meso Scale Diagnostics, LLC (U.S.), Singulex, Inc. (U.S.), BioSims Technologies (France), Cisbio Bioassays (France), and Signosis, Inc. (U.S.).